Introduction to
FFPE Blocks with TruSight Oncology 500 Data
Buy FFPE Blocks With TSO500 Data for Oncology Research
FFPE blocks with TSO500 data provide preserved tumour tissue linked to results generated using the TruSight Oncology 500 assay or a specified version of the platform. Depending on the workflow and assay version, the data may cover hundreds of cancer-associated genes and several alteration classes, potentially including small variants, copy-number changes, gene fusions and splice variants. Certain reports may also contain genomic signatures such as microsatellite instability and tumour mutational burden.
Researchers should verify exactly which assay version, modules and analytical pipeline were used rather than assuming that every TSO500 report contains identical information. The physical tissue can support IHC, FISH, PCR, spatial profiling or orthogonal confirmation of selected findings. Pathology review should establish diagnosis, tumour content, necrosis and remaining material. Researchers should also confirm whether the sequencing was performed on the supplied block or matched tissue from the same patient. Properly documented FFPE blocks with TSO500 data can support oncology research, biomarker validation and molecular cohort development.
FFPE Tumor Blocks With TruSight Oncology 500 Results
FFPE tumour blocks with TruSight Oncology 500 results can help researchers study genomic alterations across different cancer types while retaining access to the matched physical tissue. The associated report may identify relevant DNA and RNA alterations and selected genomic signatures, depending on the assay configuration and result quality. Researchers can use the FFPE block for additional sectioning, nucleic-acid extraction, immunohistochemistry, in situ hybridisation or confirmatory molecular testing. Before selection, the report should be reviewed for sequencing quality, tumour percentage, detected variants and any limitations affecting interpretation.
Optimized for DNA Sequencing
NGS-Ready FFPE Tissue Blocks
Reliable RNA Profiling Samples
Clinically Annotated FFPE Blocks With TSO500 Data
Clinically annotated FFPE blocks with TSO500 data combine broad molecular findings with pathology and available patient-level information. Clinical annotations may include age, sex, diagnosis, histological subtype, stage, grade, treatment exposure, response and follow-up. Researchers should specify required fields before sourcing because the completeness of longitudinal information can vary considerably among cohorts. The TSO500 documentation should identify the assay version, DNA and RNA components used, sequencing quality and reported alterations.
Clinically Annotated Tissue Samples
FFPE blocks supplied with relevant clinical details for reliable genomic research.
Comprehensive Pathology Data Included
Each sample includes diagnosis, grade, stage, tumor content, and pathology information.
Optimized for Genomic Analysis
Samples are suitable for DNA, RNA, NGS, mutation analysis, and molecular profiling.
Reliable Samples for NGS
Quality-controlled FFPE blocks support accurate sequencing and reproducible genomic results.
Source TSO500-Profiled FFPE Samples for Biomarker Studies
TSO500-profiled FFPE samples can be sourced according to cancer type, genomic alteration, histological subtype and clinical characteristics. Researchers may request cases carrying specific mutations, copy-number changes, gene fusions, microsatellite instability or defined tumour mutational burden values. The request should specify whether a complete sequencing report, selected result fields or underlying genomic files are required. Sample eligibility should be evaluated using the assay version, sequencing quality, panel coverage, tumour content and variant classification.
Where a particular alteration is central to the study, researchers may request orthogonal confirmation through PCR, FISH, IHC or repeat sequencing. The FFPE material should undergo pathology review to determine whether sufficient representative tumour remains for planned analyses. Carefully selected positive and negative cases can support antibody assessment, assay development, spatial research and biomarker validation. A transparent manifest linking each block to its TSO500 findings is essential for maintaining traceability and scientific reliability.
FFPE Blocks With TSO500 Data for Precision Oncology
FFPE blocks with TSO500 data can support precision-oncology research by helping investigators identify and study molecularly defined tumour subgroups. The profiling results may reveal actionable alterations, resistance-associated variants, gene fusions, copy-number changes or genomic signatures relevant to therapeutic research. The matched tissue enables researchers to examine how these molecular findings correspond to protein expression, histological features and characteristics of the tumour microenvironment. Interpretation should account for tumour purity, sequencing quality, assay configuration and the clinical significance assigned to reported variants.
Researchers should not treat every detected alteration as therapeutically actionable without additional scientific and clinical evidence. Where treatment and outcome data are available, the specimens may support retrospective investigations of response or resistance. Proper consent, ethical approval and data-use permissions should cover both tissue and genomic information. Carefully curated TSO500-profiled FFPE blocks can provide a useful research resource for biomarker discovery, assay development and molecular stratification.
Order Quality-Controlled FFPE Tumor Blocks With TSO500 Results
Ordering quality-controlled FFPE tumour blocks with TSO500 results requires predefined pathology, molecular and data criteria. Researchers should state the required tumour indication, stage, histology, specimen site, tissue quantity, minimum tumour percentage and maximum necrosis. Molecular criteria may include particular variants, fusions, copy-number alterations, microsatellite instability or tumour mutational burden ranges. The TSO500 assay version, report format and required quality metrics should also be identified. Before shipment, a pathologist can review a recent H&E slide and confirm diagnosis, tumour content and block sufficiency. The associated sequencing report should be checked to ensure that it corresponds to the supplied specimen and supports the requested molecular classification. Additional services may include slide preparation, tissue curls, macrodissection or confirmatory testing. Clear acceptance criteria and replacement provisions can address samples that fail tissue or molecular quality control, helping researchers receive a consistent and research-ready cohort.
General Questions
Frequent Asked Questions!!
FFPE blocks for genomics are formalin-fixed, paraffin-embedded tissue samples used for DNA, RNA, and biomarker analysis. They are widely used in cancer genomics, molecular pathology, translational research, and retrospective studies.
FFPE tissue blocks are valuable because they preserve tissue architecture and molecular material for long-term storage. Researchers can use them for sequencing, mutation analysis, biomarker discovery, and validation studies.
Yes. DNA can be extracted from FFPE blocks using validated extraction kits and optimized laboratory protocols. DNA quality depends on fixation time, block age, tissue type, tumor content, and storage conditions.
Yes. RNA can be extracted from FFPE tissue, although it is often fragmented because of formalin fixation. Specialized FFPE RNA extraction methods can provide material suitable for targeted RNA sequencing, gene expression studies, and fusion analysis.
Yes. High-quality FFPE blocks are commonly used for next-generation sequencing, including targeted sequencing panels, whole-exome sequencing, RNA sequencing, and selected whole-genome applications.
Tumor content requirements depend on the study design and testing method. Many molecular and NGS studies require at least 20% tumor content, while some projects may require 30%, 50%, or higher tumor percentage. Pathologist review can be performed to confirm tumor content before shipment
FFPE blocks can support mutation testing, copy number analysis, gene fusion detection, microsatellite instability testing, tumor mutational burden analysis, methylation studies, and targeted DNA or RNA sequencing.
Yes. FFPE cancer tissue blocks are extensively used to study genomic alterations in lung, breast, colorectal, prostate, ovarian, pancreatic, liver, kidney, and other tumor types.
Researchers can purchase FFPE blocks from qualified biospecimen suppliers, biobanks, pathology laboratories, hospitals, and research networks that provide ethically sourced and clinically annotated human tissue samples.
Researchers should confirm diagnosis, tissue type, tumor percentage, necrosis percentage, fixation details, block age, specimen size, available clinical data, pathology review, consent status, and intended research-use permissions.
Yes. Clinically annotated FFPE blocks may include donor age, sex, diagnosis, grade, stage, TNM classification, treatment history, pathology report, mutation status, and clinical outcome data.